BeiGene Books $9 Million Milestone from Merck Serono

BeiGene, a Beijing novel drug developer, received a $9 million milestone from Merck Serono for starting a Phase I trial of BGB-290, a second generation PARP inhibitor. Less than a year ago, Merck Serono and BeiGene entered a co-development agreement for BGB-290 in a deal than included an unspecified upfront payment and $232 million of milestones. It was the second transaction between the two companies and the second to trigger a milestone. In May, BeiGene received a $5 million milestone from Merck Serono for starting a clinical trial of BGB-283, a second-generation BRAF inhibitor. More details.... Stock Symbol: (XETRA: MRK) Share this with colleagues: // //